Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vandenberghe

Showing results (171-180 of 185) with videos related to

Pageof 19
Sort By:
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Cancer Cell|June 14, 2011
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemiaThomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, et al.
British Journal of Haematology|May 17, 2011
EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cellsAn De Weer, Joni Van der Meulen, Pieter Rondou, et al.
The Journal of Allergy and Clinical Immunology|August 13, 2021
Overactive WASp in X-linked neutropenia leads to aberrant B-cell division and accelerated plasma cell generationMinghui He, Mezida B Saeed, Julien Record, et al.
Nature Genetics|December 25, 2012
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Zeynep Kalender Atak, Ning Li, et al.
Blood|February 14, 2014
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesisJulia Skokowa, Doris Steinemann, Jenny E Katsman-Kuipers, et al.
Haematologica|August 5, 2018
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphomaRenate De Smedt, Sofie Peirs, Julie Morscio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Cancer|November 28, 2018
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machineryGiorgia Simonetti, Antonella Padella, Italo Farìa do Valle, et al.
Cancer Cell|April 20, 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine, Martha Wadleigh, Jan Cools, et al.
Pageof 19

Showing results (171-180 of 185) with videos related to

Sort By:
Pageof 19
The New England Journal of Medicine|March 28, 2003
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndromeJan Cools, Daniel J DeAngelo, Jason Gotlib, et al.
Cancer Cell|June 14, 2011
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemiaThomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, et al.
British Journal of Haematology|May 17, 2011
EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cellsAn De Weer, Joni Van der Meulen, Pieter Rondou, et al.
The Journal of Allergy and Clinical Immunology|August 13, 2021
Overactive WASp in X-linked neutropenia leads to aberrant B-cell division and accelerated plasma cell generationMinghui He, Mezida B Saeed, Julien Record, et al.
Nature Genetics|December 25, 2012
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemiaKim De Keersmaecker, Zeynep Kalender Atak, Ning Li, et al.
Blood|February 14, 2014
Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesisJulia Skokowa, Doris Steinemann, Jenny E Katsman-Kuipers, et al.
Haematologica|August 5, 2018
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphomaRenate De Smedt, Sofie Peirs, Julie Morscio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative GroupStefan Gröschel, Richard F Schlenk, Jan Engelmann, et al.
Cancer|November 28, 2018
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machineryGiorgia Simonetti, Antonella Padella, Italo Farìa do Valle, et al.
Cancer Cell|April 20, 2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine, Martha Wadleigh, Jan Cools, et al.
Pageof 19